electroCore (ECOR) 10-Q 12 Nov 20 2020 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2020	Nov. 08, 2020
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q3
Trading Symbol	ECOR
Entity Registrant Name	electroCore, Inc.
Entity Central Index Key	0001560258
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	true
Entity Current Reporting Status	Yes
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		45,454,457
Entity File Number	001-38538
Entity Tax Identification Number	20-3454976
Entity Address, Address Line One	150 Allen Road
Entity Address, Address Line Two	Suite 201
Entity Address, City or Town	Basking Ridge
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	07920
City Area Code	973
Local Phone Number	290-0097
Entity Interactive Data Current	Yes
Title of 12(b) Security	Common Stock, par value $0.001 per share
Security Exchange Name	NASDAQ
Entity Incorporation, State or Country Code	DE
Document Quarterly Report	true
Document Transition Report	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 3,832,454	$ 13,563,791
Marketable securities	22,135,211	10,495,350
Accounts receivable, net	175,954	496,140
Inventories, net	793,216	890,992
Prepaid expenses and other current assets	1,663,699	1,087,111
Total current assets	28,600,534	26,533,384
Inventories, non-current	6,133,878	6,020,180
Property and equipment, net	267,549	345,236
Operating lease right of use assets	1,153,939	1,430,641
Other assets	919,421	1,132,238
Total assets	37,075,321	35,461,679
Current liabilities:
Accounts payable	2,028,439	5,208,979
Accrued expenses and other current liabilities	2,535,941	3,337,379
Notes payable	732,305	111,878
Current portion of operating lease liabilities	514,934	486,445
Total current liabilities	5,811,619	9,144,681
Noncurrent liabilities:
Operating lease liabilities	1,036,117	1,419,880
Notes payable, non-current	1,331,559
Total liabilities	8,179,295	10,564,561
Commitments and contingencies
Stockholders' equity:
Preferred Stock, par value $0.001 per share; 10,000,000 shares authorized at September 30, 2020 and December 31, 2019; 0 shares issued and outstanding at September 30, 2020 and December 31, 2019
Common Stock, par value $0.001 per share; 500,000,000 shares authorized at September 30, 2020 and December 31, 2019; 45,199,088 shares issued and outstanding at September 30, 2020 and 29,835,183 shares issued and outstanding at December 31, 2019	45,199	29,835
Additional paid-in capital	129,071,951	107,752,066
Accumulated deficit	(100,666,379)	(83,479,098)
Accumulated other comprehensive loss	(190,355)	(41,295)
Total electroCore, Inc. stockholders' equity	28,260,416	24,261,508
Noncontrolling interest	635,610	635,610
Total equity	28,896,026	24,897,118
Total liabilities and equity	$ 37,075,321	$ 35,461,679

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2020	Dec. 31, 2019
Statement Of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	45,199,088	29,835,183
Common stock, shares outstanding	45,199,088	29,835,183

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Income Statement [Abstract]
Net sales	$ 1,080,841	$ 682,993	$ 2,567,567	$ 1,715,337
Cost of goods sold	347,504	353,939	918,605	766,173
Gross profit	733,337	329,054	1,648,962	949,164
Operating expenses:
Research and development	629,002	2,274,855	3,182,646	8,279,432
Selling, general and administrative	4,592,936	8,143,356	16,426,991	28,155,604
Restructuring and other related charges		804,643	464,606	1,997,292
Total operating expenses	5,221,938	11,222,854	20,074,243	38,432,328
Loss from operations	(4,488,601)	(10,893,800)	(18,425,281)	(37,483,164)
Other (income)/expense
Interest and other income	(5,719)	(206,057)	(80,460)	(850,062)
Other expense	3,522		13,350	16,692
Total other (income)/expense	(2,197)	(206,057)	(67,110)	(833,370)
Loss before income taxes	(4,486,404)	(10,687,743)	(18,358,171)	(36,649,794)
Benefit from income taxes (see Note 14)			1,170,890
Net loss	$ (4,486,404)	$ (10,687,743)	$ (17,187,281)	$ (36,649,794)
Net loss per share of common stock - Basic and Diluted (see Note 13)	$ (0.10)	$ (0.36)	$ (0.47)	$ (1.25)
Weighted average common shares outstanding - Basic and Diluted (see Note 13)	44,030,685	29,352,026	36,847,548	29,339,384

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Statement Of Income And Comprehensive Income [Abstract]
Net loss	$ (4,486,404)	$ (10,687,743)	$ (17,187,281)	$ (36,649,794)
Other comprehensive (loss) income:
Foreign currency translation adjustment	(81,602)	17,674	(145,617)	5,935
Unrealized (loss)/gain on securities, net of taxes as applicable	(2,210)	(10,781)	(3,443)	45,628
Other comprehensive (loss) income	(83,812)	6,893	(149,060)	51,563
Comprehensive loss	$ (4,570,216)	$ (10,680,850)	$ (17,336,341)	$ (36,598,231)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($)		Total	Common Stock	Additional paid-in capital	Accumulated deficit	Accumulated other comprehensive income	Total electroCore, Inc. stockholders' equity	Noncontrolling interest
Balances, beginning of period at Dec. 31, 2018		$ 66,185,701	$ 29,450	$ 103,791,013	$ (38,331,215)	$ 60,843	$ 65,550,091	$ 635,610
Balances, beginning of period, shares at Dec. 31, 2018			29,450,035
Net loss		(13,861,530)			(13,861,530)		(13,861,530)
Other comprehensive income		83,713				83,713	83,713
Issuance of warrants in settlement of lawsuit		16,692		16,692			16,692
Issuance of stock related to employee compensation plans, net of forfeitures			$ 183	(183)
Issuance of stock related to employee compensation plans, net of forfeitures, shares			183,205
Stock based compensation		744,032		744,032			744,032
Balances, end of period at Mar. 31, 2019		53,168,608	$ 29,633	104,551,554	(52,192,745)	144,556	52,532,998	635,610
Balances, end of period, shares at Mar. 31, 2019			29,633,240
Net loss		(12,100,520)			(12,100,520)		(12,100,520)
Other comprehensive income		(39,098)				(39,098)	(39,098)
Stock based compensation		726,799	(52)	726,851			726,799
Balances, end of period at Jun. 30, 2019		41,755,789	$ 29,581	105,278,405	(64,293,265)	105,458	41,120,179	635,610
Balances, end of period, shares at Jun. 30, 2019			29,581,691
Net loss		(10,687,743)			(10,687,743)		(10,687,743)
Other comprehensive income		6,893				6,893	6,893
Issuance of stock related to employee compensation plans, net of forfeitures			$ 28	(28)
Issuance of stock related to employee compensation plans, net of forfeitures, shares			28,202
Stock based compensation		1,219,575		1,219,575			1,219,575
Stock based compensation, Shares			(51,549)
Stock cancellations			$ (141)	141
Stock cancellations, shares			(140,927)
Balances, end of period at Sep. 30, 2019		32,294,514	$ 29,468	106,498,093	(74,981,008)	112,351	31,658,904	635,610
Balances, end of period, shares at Sep. 30, 2019			29,468,966
Balances, beginning of period at Dec. 31, 2019		24,897,118	$ 29,835	107,752,066	(83,479,098)	(41,295)	24,261,508	635,610
Balances, beginning of period, shares at Dec. 31, 2019			29,835,183
Net loss		(7,959,349)			(7,959,349)		(7,959,349)
Other comprehensive income		51,148				51,148	51,148
Equity financing commitment fee	[1]		$ 462	(462)
Equity financing commitment fee, shares	[1]		461,676
Issuance of stock related to employee compensation plans, net of forfeitures			$ 125	(125)
Issuance of stock related to employee compensation plans, net of forfeitures, shares			124,568
Stock based compensation		744,865		744,865			744,865
Balances, end of period at Mar. 31, 2020		17,733,782	$ 30,422	108,496,344	(91,438,447)	9,853	17,098,172	635,610
Balances, end of period, shares at Mar. 31, 2020			30,421,427
Net loss		(4,741,528)			(4,741,528)		(4,741,528)
Other comprehensive income		(116,396)				(116,396)	(116,396)
Issuance of stock		7,831,535	$ 8,028	7,823,507			7,831,535
Issuance of stock, shares			8,028,372
Equity financing commitment fee	[1]		$ 181	(181)
Equity financing commitment fee, shares	[1]		181,273
Financing fees		(167,299)		(167,299)			(167,299)
Issuance of stock related to employee compensation plans, net of forfeitures			$ 184	(184)
Issuance of stock related to employee compensation plans, net of forfeitures, shares			184,073
Stock based compensation		1,002,758		1,002,758			1,002,758
Balances, end of period at Jun. 30, 2020		21,542,852	$ 38,815	117,154,945	(96,179,975)	(106,543)	20,907,242	635,610
Balances, end of period, shares at Jun. 30, 2020			38,815,145
Net loss		(4,486,404)			(4,486,404)		(4,486,404)
Other comprehensive income		(83,812)				(83,812)	(83,812)
Issuance of stock		11,203,661	$ 6,080	11,197,581			11,203,661
Issuance of stock, shares			6,079,676
Equity financing commitment fee	[1]		$ 49	(49)
Equity financing commitment fee, shares	[1]		49,565
Financing fees		(23,199)		(23,199)			(23,199)
Issuance of stock related to employee compensation plans, net of forfeitures			$ 255	(255)
Issuance of stock related to employee compensation plans, net of forfeitures, shares			254,702
Stock based compensation		742,928		742,928			742,928
Balances, end of period at Sep. 30, 2020		$ 28,896,026	$ 45,199	$ 129,071,951	$ (100,666,379)	$ (190,355)	$ 28,260,416	$ 635,610
Balances, end of period, shares at Sep. 30, 2020			45,199,088
[1]	Reflects commitment shares issued in accordance with the Company's equity facility purchase agreement with Lincoln Park Capital. For additional information see Note 12. Lincoln Park Stock Purchase Agreement.

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Cash flows from operating activities:
Net loss	$ (17,187,281)	$ (36,649,794)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation	2,490,551	2,690,406
Depreciation and amortization	288,589	152,255
Amortization of marketable securities discount	23,422	(480,840)
Cloud computing arrangement implementation costs		(1,114,568)
Legal expense settled with stock	156,434
Net noncash lease expense	(82,204)	411,142
Noncash portion of litigation settlement		16,692
Other	14,893	(157,759)
Changes in operating assets and liabilities:
Accounts receivable, net	320,186	(485,778)
Inventories	(15,922)	(3,171,868)
Prepaid expenses and other current assets	(586,588)	274,199
Accounts payable	(1,631,839)	3,219,105
Accrued expenses and other current liabilities	(801,439)	(656,734)
Net cash used in operating activities	(17,011,198)	(35,953,542)
Cash flows from investing activities:
Purchase of marketable securities	(22,166,376)	(35,216,037)
Proceeds from maturities of marketable securities	10,500,000	69,766,000
Purchases of property and equipment		(72,241)
Net cash (used in) provided by investing activities	(11,666,376)	34,477,722
Cash flows from financing activities:
Proceeds from shares issued, net of related expenses	17,139,563
Proceeds from notes issued	2,558,360	807,347
Repayments of notes issued	(606,374)	(346,006)
Net cash provided by financing activities	19,091,549	461,341
Effect of changes in exchange rates on cash and cash equivalents	(145,312)	(37,299)
Net decrease in cash and cash equivalents	(9,731,337)	(1,051,778)
Cash and cash equivalents – beginning of period	13,563,791	7,600,284
Cash and cash equivalents – end of period	3,832,454	6,548,506
Supplemental cash flows disclosures:
Proceeds from sale of state net operating losses	1,170,890
Interest paid	9,366	3,457
Income taxes paid	3,254
Supplemental schedule of noncash activity:
Prepaid lease payments included in right of use assets		42,857
Accounts payable paid through issuance of common stock	1,548,702
Insurance premium financing	$ 654,563	$ 461,341

The Company

The Company	9 Months Ended
	Sep. 30, 2020
Organization Consolidation And Presentation Of Financial Statements [Abstract]
The Company	Note 1. The Company electroCore, Inc. (“electroCore” or the “Company”) is a medical device company, engaged in the commercialization and development of a platform non-invasive Vagus Nerve Stimulation (“ nVNS”) therapy that can be self-administered by patients. electroCore was founded in 2005 and has primarily focused on headache conditions (migraine and cluster headache). In July 2020, the U.S. Food and Drug Administration (“FDA”) granted the Company an Emergency Use Authorization (EUA) authorizing the use of the Company’s gammaCore Sapphire™ CV nVNS therapy at home or in a healthcare setting to acutely treat adult patients with known or suspected COVID-19 who are experiencing exacerbation of asthma-related dyspnea and reduced airflow, and for whom approved drug therapies are not tolerated or provide insufficient symptom relief. electroCore, headquartered in New Jersey, has two wholly owned subsidiaries: electroCore Germany GmbH, and electroCore UK Ltd. The Company has ceased its operations in Germany, although sales to Germany are still supported by electroCore UK Ltd. In addition, an affiliate, electroCore (Aust) Pty Limited (“electroCore Australia”), is subject to electroCore’s control on a basis other than voting interests and is a variable interest entity (“VIE”), for which electroCore is the primary beneficiary.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2020
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2 . Summary of Significant Accounting Policies (a) Basis of Presentation The accompanying condensed consolidated financial statements were prepared in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”) and with instructions to Form 10-Q and Article 10 of Regulation S-X under the Securities Exchange Act of 1934, as amended. In the opinion of management, the Company has made all necessary adjustments, which include normal recurring adjustments necessary for a fair presentation of the Company’s condensed consolidated financial position and results of operations for the interim periods presented. Certain information and disclosures normally included in the annual consolidated financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. These interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and accompanying notes for the year ended included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 30 2020 are not necessarily indicative of the results to be expected for a full year, any other interim periods or any future year or period. (b) Principles of Consolidation The accompanying condensed consolidated financial statements include the accounts of electroCore and its wholly owned subsidiaries. electroCore Australia, a VIE for which electroCore is the primary beneficiary, is also consolidated with the non-controlled equity presented as a non-controlling interest. All intercompany balances and transactions have been eliminated in consolidation. (c) Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of these condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant items subject to such estimates and assumptions include allowances for doubtful accounts, trade credits, rebates, co-payment assistance and sales returns, valuation of inventory , stock compensation, and contingencies. (d) Credit Losses on Financial Instruments In June 2016, the Financial Accounting Standard Board ("FASB") issued guidance on the measurement of credit losses which requires measurement and recognition of expected credit losses for financial assets, including trade receivables held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. The method to determine a loss is different from the existing guidance, which requires a credit loss to be recognized when it is probable. The Company adopted this guidance and determined the impact was immaterial on the consolidated to the financial statements. (e) Fair Value Measurement In August 2018, the FASB issued guidance which modified the disclosure requirements for fair value measurements. The guidance is effective for the year ended December 31, 2020. The Company adopted this guidance and it was properly reflected in the condensed consolidated financial statements. There were no material changes to the prior disclosure. (f) Recent Accounting Standards Not Yet Adopted In December 2019, the FASB issued an update to simplify the accounting for income taxes and improve consistent application by clarifying or amending existing guidance. This guidance is effective for the year ended December 31, 2021. The Company does not expect this guidance to have a material impact on its consolidated financial statements upon adoption.

Risks and Uncertainties

Risks and Uncertainties	9 Months Ended
	Sep. 30, 2020
Risks And Uncertainties [Abstract]
Risks and Uncertainties	Note 3. Risks and Uncertainties Going Concern The Company is subject to risks common to emerging medical device companies, including uncertainties related to commercialization of products and failing to secure additional funding. The Company has experienced significant net losses, and it expects to continue to incur losses for the near future as it operates its sales and marketing infrastructure, and works to increase market acceptance of its gammaCore therapy for the acute treatment of episodic cluster headache (“eCH”), the prevention of cluster headache, and the preventive and acute treatment of migraine. The Company has never been profitable and has incurred net losses in each year since its inception. The Company incurred net losses of $4.5 million and $17.2 million for the three and , respectively. On March 27, 2020, the Company and Lincoln Park Capital Fund, LLC (“Lincoln Park”) entered into an equity facility purchase agreement pursuant to which the Company has the right to sell to Lincoln Park shares of common stock having an aggregate value of up to $ 25.0 During the nine months ended September 30, 2020, the Company received net proceeds of approximately $ 17.1 On May 14, 2020, the Company entered into a Securities Purchase Agreement with its legal counsel pursuant to which it issued 1,564,345, shares of common stock, at a purchase price of $0.99 per share. Upon issuance of the shares, certain of the Company’s outstanding financial obligations to such legal counsel were deemed paid and satisfied in full. In May 2020, the Company received $1.4 million in connection with its Paycheck Protection Program (“PPP”) loan under the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”). Under the terms of the CARES Act, PPP loan recipients can be granted forgiveness for all or a portion of the loan granted under the PPP, with such forgiveness to be determined, subject to limitations, based on the use of the loan proceeds for payment of certain expenses and loan recipients maintaining their payroll levels over certain required thresholds under the PPP. The terms of any forgiveness also may be subject to further requirements in any regulations and guidelines the Small Business Administration (“SBA”) may adopt. No assurance can be provided that the Company will obtain forgiveness of the PPP Loan in whole or in part. Official guidance and interpretations of the requirements of the program have been limited and have been changing over time. Despite the Company’s good-faith belief that it has properly satisfied all eligibility requirements for the PPP loan, there has been increasing scrutiny of public companies that received loans, and there can be no assurance that the Company will not become subject to regulatory or other scrutiny, including a request or requirement for repayment of some or all of the loan. The Company may be eligible, from time to time, to receive cash from the sale of its Net Operating Losses under the State of New Jersey’s NOL Transfer Program. On May 6, 2020, the Company received a net cash amount of approximately $1.2 million from the sale of its state NOLs and research and development tax credits for the year ended December 31, 2018. The Company’s expected cash requirements for 2020 and beyond are based on the commercial success of its products and its ability to reduce operating expenses. There are significant risks and uncertainties as to its ability to achieve these operating results, including as a result of the adverse impact on its headache business from the COVID-19 pandemic and significant potential investment necessary to generate potential sales of gammaCore Sapphire™ CV. Due to these risks and uncertainties, the Company may need to reduce its activities significantly more than in its current operating plan and cash flow projections assume in order to fund its operations beyond one year of the date these financial statements are issued. There can be no assurance that the Company will have sufficient cash flow and liquidity to fund its planned activities, which could force it to significantly reduce or curtail its activities and, ultimately, potentially cease operations. There is no assurance that the Company will generate sufficient funding through its operating results or financing activity, raising substantial doubt about the Company’s ability to continue as a going concern within one year of the date these financial statements are issued. The accompanying financial statements do not include any adjustment that might result from the outcome of this uncertainty. Concentration of Revenue Risks The Company earns a significant amount of its revenue (i) in the U.S. from the Department of Veterans Affairs and Department of Defense pursuant to its qualifying contract under the Federal Supply Schedule and open market sales to individual Department of Veterans Affairs facilities and (ii) in the United Kingdom from the National Health Service. Net sales from these two channels represented 84.0% 87.2% nine months ended September 30, 2020 , and 63.4% and 47.5% for the and nine months ended September 30, 2019 , respectively. Foreign Currency Exchange The Company has foreign currency exchange risk related to revenue and operating expenses in currencies other than the local currencies in which it operates. The Company is exposed to currency risk from the potential changes in functional currency values of its assets, liabilities, and cash flows denominated in foreign currencies COVID-19 Risks and Uncertainties The Company continues to monitor the impact of the COVID-19 pandemic on all aspects of its business and geographies, including how it will impact business partners. While the Company experienced disruptions during the nine months ended September 30, 2020 from the COVID-19 pandemic, it is unable to predict the full impact that the COVID-19 pandemic may have on its financial condition, results of operations and cash flows due to numerous uncertainties. These uncertainties include the scope, severity and duration of the pandemic, the actions taken to contain the pandemic or mitigate its impact and the direct and indirect economic effects of the pandemic and containment measures, among others. The outbreak of COVID-19 in many countries, including the United States, has significantly adversely impacted global economic activity and has contributed to significant volatility and negative pressure in financial markets. In addition, because the COVID-19 pandemic affected, among other things, the Company's access to prescribing physicians and their access to headache patients, on March 23, 2020 the Company suspended its earlier full-year revenue guidance until it could better understand the trajectory of its business, as well as announced a reduction in its activities, and adjusted its cash runway expectations in response to the potential adverse impact caused by the COVID-19 pandemic. Compared to its earlier expectations, the Company believes that its results for the nine months ended September 30, 2020 reflect a negative impact from, among other things, the global pandemic. Moreover, the Company's expectations for the remainder of 2020 have also been adversely affected by both the uncertainty and potential negative impact of the global pandemic, which it believes may also have had an adverse effect on its access to debt and equity capital markets. Depending upon the duration and severity of the pandemic, the continuing effect on the Company's results and outlook over the long term remains uncertain.

Revenue Recognition

Revenue Recognition	9 Months Ended
	Sep. 30, 2020
Revenue From Contract With Customer [Abstract]
Revenue Recognition	Note 4 . Revenue Recognition Geographical Net Sales The following table presents net sales disaggregated by geographic area: For the three months ended September 30, For 2020 2019 2020 2019 Geographic Market United States $ 800,767 $ 491,722 $ 1,759,477 $ 1,211,318 Europe 278,340 187,639 801,055 494,765 Other 1,734 3,632 7,035 9,254 Total Net Sales $ 1,080,841 $ 682,993 $ 2,567,567 $ 1,715,337 Performance Obligations Revenue, net of discounts, vouchers, rebates, returns, and co-payment assistance is solely generated from the sales of gammaCore products. Revenue is recognized when delivery of the product is completed. The Company deems control to have transferred upon the completion of delivery because that is the point in which (1) it has a present right to payment for the product, (2) it has transferred the physical possession of the product, (3) the customer has a legal title to the product, (4) the customer has risks and rewards of ownership and (5) the customer has accepted the product. After the products have been delivered and control has transferred, the Company has no Revenue is measured based on the consideration that the Company expects to receive in exchange for gammaCore, which represents the transaction price. The transaction price includes the fixed per-unit price of the product and variable consideration in the form of trade credits, rebates, and co-payment assistance. The per-unit price is based on the Company’s established wholesale acquisition cost less a contractually agreed upon discount with the customer. Trade credits are discounts that are contingent upon a timely remittance of payment and are estimated based on historical experience. Generally, agreed upon payment terms with customers are within 30 days of shipment. Accordingly, contracts with customers do not include a significant financing component. Contract Balances The Company generally invoices the customer and recognizes revenue once its performance obligations are satisfied, at which point payment is unconditional. Accordingly, under Accounting Standards Codification ("ASC") 606, the Company’s contracts with customers did not give rise to contract assets or liabilities during the three and and 2019.

Cash, Cash Equivalents and Mark

Cash, Cash Equivalents and Marketable Securities	9 Months Ended
	Sep. 30, 2020
Investments Debt And Equity Securities [Abstract]
Cash, Cash Equivalents and Marketable Securities	Note 5 . Cash, Cash Equivalents and Marketable Securities The following tables summarize the Company’s cash, cash equivalents and marketable securities as of and . As of Amortized Cost Unrealized Gain Unrealized (Loss) Fair Value Cash and cash equivalents $ 3,832,454 $ — $ — $ 3,832,454 U.S. Treasury Bonds $ 22,138,304 $ — $ (3,093 ) $ 22,135,211 Total marketable securities $ 22,138,304 $ — $ (3,093 ) $ 22,135,211 Total cash, cash equivalents, and marketable securities $ 25,970,758 $ — $ (3,093 ) $ 25,967,665 A s of December 31, 2019 Amortized Cost Unrealized Gain Unrealized (Loss) Fair Value Cash and cash equivalents $ 13,564,252 $ — $ (461 ) $ 13,563,791 U.S. Treasury Bonds $ 10,494,539 $ 811 $ — $ 10,495,350 Total marketable securities $ 10,494,539 $ 811 $ — $ 10,495,350 Total cash, cash equivalents, and marketable securities $ 24,058,791 $ 811 $ (461 ) $ 24,059,141

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2020
Fair Value Disclosures [Abstract]
Fair Value Measurements	Note 6 . Fair Value Measurements Financial assets and liabilities carried at fair value are classified and disclosed in one of the following three levels of the fair value hierarchy: • Level 1—Quoted prices in active markets for identical assets or liabilities. • Level 2—Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. • Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. A summary of the assets and liabilities carried at fair value in accordance with the hierarchy d efined above is as follows: Fair Value Hierarchy September 30, 2020 Total Level 1 Level 2 Level 3 Assets Cash and cash equivalents $ 3,832,454 $ 3,832,454 $ — $ — Marketable Securities: U.S. treasury bonds 22,135,211 22,135,211 — — Total $ 25,967,665 $ 25,967,665 $ — $ — Fair Value Hierarchy December 31, 2019 Total Level 1 Level 2 Level 3 Assets Cash and cash equivalents $ 13,563,791 $ 13,563,791 $ — $ — Marketable Securities: U.S. treasury bonds 10,495,350 10,495,350 — — Total $ 24,059,141 $ 24,059,141 $ — $ — The Company recognizes transfers between levels of the fair value hierarchy as of the end of the reporting period. There were no transfers within the hierarchy during the three and and year ended December 31, 2019. The carrying amount of the Company’s receivables and payables approximate their fair values due to their short maturities.

Inventories

Inventories	9 Months Ended
	Sep. 30, 2020
Inventory Disclosure [Abstract]
Inventories	Note 7 . Inventories As of and , inventories consisted of the following: September 30, December 31, 2020 2019 Raw materials $ 1,503,808 $ 1,065,345 Work in process 4,656,723 5,314,763 Finished goods 766,563 531,064 Total inventory 6,927,094 6,911,172 Less: noncurrent (6,133,878 ) (6,020,180 ) Total - current $ 793,216 $ 890,992 As of September 30, 2020 and , the Company’s reserves for obsolete inventory totaled $287,544. The Company records charges for obsolete inventory in cost of goods sold. As of September 30, 2020 and December 31, 2019, noncurrent inventory was comprised of approximately $1.8 million and $1.0 million of raw materials, respectively, and $4.3 million and $5.0 million of work in process, respectively.

Leases

Leases	9 Months Ended
	Sep. 30, 2020
Leases [Abstract]
Leases	Note 8. Leases For the three and nine months ended September 30, 2020, the Company recognized lease expense of $149,731 and $422,765, and $186,037 and $599,322 for the three and nine months ended September 30, 2019, respectively. This expense does not include non- lease co The tables below provide the details of the right of use assets and lease liabilities: Supplemental Balance Sheet Information for Operating Leases September 30, 2020 December 31, 2019 Operating leases: Operating lease right of use assets $ 1,153,939 $ 1,430,641 Operating lease liabilities: Current portion of operating lease liabilities 514,934 486,445 Noncurrent operating lease liabilities 1,036,117 1,419,880 Total operating lease liabilities $ 1,551,051 $ 1,906,325 Weighted average remaining lease term (in years) 5.7 5.9 Weighted average discount rate 13.75 % 13.75 % Supplemental Statement of Cash Flows Information for Operating Leases Nine months ended September 30, 2020 2019 Noncash lease expense $ 273,070 $ 232,270 Change in operating lease liabilities $ (355,274 ) $ 178,872 Future minimum lease payments under non-cancellable operating leases as of : Remainder of 2020 $ 127,959 2021 743,818 2022 337,254 2023 142,892 2024 146,044 2025 and thereafter 676,260 Total future minimum lease payments 2,174,227 Less: Amounts representing interest (623,176 ) Total $ 1,551,051

Cloud Computing Arrangement

Cloud Computing Arrangement	9 Months Ended
	Sep. 30, 2020
Cloud Computing Arrangement [Abstract]
Cloud Computing Arrangement	Note 9. Cloud Computing Arrangement In 2018, the Company entered into a contract to obtain a cloud computing arrangement (“CCA”). In accordance with Accounting Standards Update 2018-15, the implementation costs incurred in the CCA are deferred and recognized as other assets and are amortized to expense over the noncancelable term of the arrangement. The implementation of this CCA was completed on September 30, 2019. Beginning July 1, 2019, the Company went live with the cloud computing system and all future related costs are expensed as incurred. In July 2019, the Company began amortizing the related deferred costs over the remaining period of the noncancelable arrangement. Amortization costs for the three and nine months ended September 30, 2020 were $70,519 and $211,556, respectively. As of September 30, 2020, and December 31, 2019 the net book value of the CCA was $869,729 and $1,081,284, respectively, and is included under the caption Other assets in the Company’s Condensed Consolidated Balance Sheet. The remaining term of the lease as of September 30, 2020 is approximately 3

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	9 Months Ended
	Sep. 30, 2020
Payables and Accruals [Abstract]
Accrued Expenses and Other Current Liabilities	Note 10 . Accrued Expenses and Other Current Liabilities Accrued expenses as of and consisted of the following: September 30, December 31, 2020 2019 Accrued professional fees $ 411,880 $ 1,255,494 Accrued bonuses 1,105,166 804,082 Other employee related expenses 415,441 836,754 Other 603,454 441,049 $ 2,535,941 $ 3,337,379

Notes Payable

Notes Payable	9 Months Ended
	Sep. 30, 2020
Notes Payable [Abstract]
Note Payable	Note 11. Notes Payable Loan Under the PPP On May 4, 2020, the Company received proceeds of $1.4 million in connection with a promissory note (the “Note”) entered into with Citibank, N.A. (the “Lender”) evidencing an unsecured loan (the “Loan”) under the PPP. The PPP is a program of the SBA established under the CARES Act. Under the PPP, the proceeds of the Loan may be used for payroll and certain covered interest payments, lease payments and utility payments (“Qualifying Expenses”). The Company intends to use the entire Loan amount for Qualifying Expenses under the PPP. The interest rate on the Loan is 1.0% per annum. The Note matures on February 2, 2023 Under the terms of the CARES Act, PPP loan recipients can be granted forgiveness for all or a portion of the loan granted under the PPP, with such forgiveness to be determined, subject to limitations, based on the use of the loan proceeds for payment of Qualifying Expenses and the recipient maintaining its payroll levels over certain required thresholds under the PPP. The terms of any forgiveness also may be subject to further requirements in any regulations and guidelines the SBA may adopt. No assurance can be provided that the Company will obtain forgiveness of the Note in whole or in part. Official guidance and interpretations of the requirements of the program have been limited and have been changing over time. Despite the Company’s good-faith belief that it properly satisfied all eligibility requirements for the PPP loan, there has been increasing scrutiny of public companies that received loans, and there can be no assurance that the Company will not become subject to regulatory or other scrutiny, including a request or requirement for repayment of some or all of the loan. The Company has accounted for the Loan in accordance with FASB ASC Topic 470, Debt . Accordingly, the Loan is reflected as a liability on its Condensed Consolidated Balance Sheet as of September 30, 2020. The Company will record a gain if the Loan is forgiven. Finance and Security Agreement On July 1, 2020, the Company entered into a Commercial Insurance Premium Finance and Security Agreement (“the Agreement”). The Agreement provides for a single borrowing by the Company of $1.2 million, with a seven-month term and an annual interest rate of 2.18%. The proceeds from this transaction were used to partially fund the premiums due under some of the Company’s insurance policies. The amounts payable are secured by the Company’s rights under such policies. The Company is required to pay monthly installments of approximately $164,800 beginning in July 2020. As of September 30, 2020, the remaining balance un der the Agreement is $ 654,563 and during the three and nine months ended September 30, 2020, the Company recognized $ in interest expense.

Stockholders' Equity

Stockholders' Equity	9 Months Ended
	Sep. 30, 2020
Stockholders Equity Note [Abstract]
Stockholders' Equity	Note 12. Stockholders’ Equity Lincoln Park Purchase Agreement On March 27, 2020, the Company and Lincoln Park entered into an equity facility purchase agreement pursuant to which the Company has the right to sell to Lincoln Park shares of common stock having an aggregate value of up to $25,000,000, subject to certain limitations and conditions set forth in the purchase agreement. Upon entering into the purchase agreement with Lincoln Park, the Company issued an aggregate of shares of common stock to Lincoln Park as a commitment fee. The fair value of these shares on the date of issuance was approximately $ . In addition, the purchase agreement provides that the Company will issue Lincoln Park an aggregate of additional shares of common stock as a further commitment fee based on the first $ of shares of common stock issued to Lincoln Park under the Purchase Agreement as Purchase Shares (as such term is defined in the purchase agreement with During the nine months ended September 30, 2020, the Company sold 9,979,676 shares of common stock under the LPC Purchase Agreement, resulting in aggregate proceeds of approximately $15.1 million to the Company. In accordance with the LPC Purchase Agreement, the Company issued an additional 692,514 shares of its common stock to Lincoln Park as a commitment fee. As of September 30, 2020, no further commitment fee shares remain issuable under the LPC Purchase Agreement. As of September 30, 2020, the Company had the right to sell under the LPC Purchase Agreement approximately $ million of additional shares of common stock. Other Securities Purchase Agreements On April 14, 2020, the Company entered into a Securities Purchase Agreement (“First SPA”) with certain accredited investors pursuant to which the Company agreed to sell an aggregate of 2,058,822 shares of common stock at a purchase price of $0.85 per share for aggregate proceeds to the Company of approximately $1.75 million. Each of the purchasers was an affiliate and/or existing shareholder of the Company, including some members of the Company’s board of directors. In addition, the purchasers were granted customary registration rights as further described in the First SPA. On May 14, 2020, the Company entered into a Securities Purchase Agreement (“Second SPA”) with its legal counsel pursuant to which the Company agreed to issue 1,564,345 shares of common stock, at a purchase price of $0.99 per share. Upon issuance of the shares, certain outstanding financial obligations of the Company owed to its legal counsel were deemed paid and satisfied in full. In addition, the Company’s legal counsel was granted customary registration rights as further described in the Second SPA. During the nine months ended September 30, 2020, the Company recorded a non-cash charge of $156,434 in connection with this transaction. On May 18, 2020, the Company entered into a third Securities Purchase Agreement (“Third SPA”) with certain accredited investors pursuant to which the Company agreed to sell an aggregate of 505,205 shares of common stock at a purchase price of $0.9178 per share,for aggregate proceeds to the Company of approximately $0.45 million. In addition, the purchasers were granted customary registration rights as further described in the Third SPA.

Net Loss Per Share

Net Loss Per Share	9 Months Ended
	Sep. 30, 2020
Earnings Per Share [Abstract]
Net Loss Per Share	Note 13. Net Loss Per Share Basic net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding adjusted to give effect to potentially dilutive securities. Restricted stock and unit awards, and stock options have not been included in the diluted loss per share calculation as their inclusion would have had an anti-dilutive effect. The potential common stock equivalents that have been excluded from the computation of diluted loss per share consist of the following: Nine months ended September 30, 2020 2019 Outstanding stock options 3,693,943 2,355,366 Nonvested restricted stock and unit awards 1,230,651 2,387,106 Stock purchase warrants 715,199 715,199 5,639,793 5,457,671

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2020
Income Tax Disclosure [Abstract]
Income Taxes	Note 14. Income Taxes The Company may be eligible, from time to time, to receive cash from the sale of its Net Operating Losses (“NOLs”) under the State of New Jersey’s NOL Transfer Program. On May 6, 2020, the Company received a net cash amount of approximately $1.2 million from the state NOLs and research and development tax credits for the year ended December 31, 2018. These sale proceeds are included under the caption Benefit from income taxes no

Stock Based Compensation

Stock Based Compensation	9 Months Ended
	Sep. 30, 2020
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock Based Compensation	Note 15 . Stock Based Compensation The following table presents a summary of activity related to stock options during the nine months ended September 30, 2020: Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Outstanding, January 1, 2020 3,131,266 $ 8.53 8.9 * Granted 1,844,298 1.28 * Exercised — — Cancelled (1,281,621 ) 11.79 * Outstanding, September 30, 2020 3,693,943 $ 5.86 8.7 $ 553,826 Exercisable, September 30, 2020 1,076,615 $ 10.97 7.7 $ 34,347 * de minimis The intrinsic value is calculated as the difference between the fair market value at and the exercise price per share of the stock options. The options granted to employees generally vest over a four-year period. The following table presents a summary of activity related to restricted stock awards (“RSAs”) granted during the nine months ended September 30, 2020: Number of Shares Weighted Average Grant Date Fair Value Nonvested January 1, 2020 127,505 $ 8.09 Granted — — Vested (53,662 ) 9.55 Cancelled (19,946 ) 9.52 Nonvested, September 30, 2020 53,897 $ 6.10 In general, RSAs granted to employees vest over a four The following table presents a summary of activity related to restricted and deferred stock units (“Stock Units”) granted during the : Number of Shares Weighted Average Grant Date Fair Value Nonvested, January 1, 2020 1,241,493 $ 2.86 Granted 732,140 0.91 Vested (528,238 ) 2.46 Cancelled (268,641 ) 4.08 Nonvested, September 30, 2020 1,176,754 $ 1.55 In general, Stock Units granted to employees vest over two four In general, annual share based compensation awards granted to the Company's non-executive directors vest over one year three years The Company recognized stock compensation expense for its equity awards as follows: Three months ended September 30, Nine months ended September 30, 2020 2019 2020 2019 Selling, general and administrative $ 541,757 $ 904,115 $ 1,789,122 $ 2,030,465 Research and development 179,664 313,533 649,485 658,014 Cost of goods sold 21,507 1,927 51,944 1,927 Total expense $ 742,928 $ 1,219,575 $ 2,490,551 $ 2,690,406 Total unrecognized compensation cost related to unvested awards as of was $5.7 million and is expected to be recognized over the next 2.4 years. Valuation Information for Stock-Based Compensation The fair value of each stock option award during the three and and 2019 was estimated on the date of grant using the Black-Scholes model. Expected volatility was based on historical volatility of the Company’s common stock. The risk-free interest rate was based on the average U.S. Treasury rate that most closely resembled the expected life of the related award. The expected term of the award was calculated using the simplified method. No dividend was assumed as the Company does not pay regular dividends on its common stock and does not anticipate paying any dividends in the foreseeable future. The weighted average assumptions used in the Black-Scholes option pricing model in valuing stock options granted in the nine months ended September 30, 2020 are summarized in the table below. No options were granted in the three months ended September 30, 2020. Nine months ended September 30, 2020 Nine months ended September 30, 2019 Fair value at grant date $ 0.98 $ 4.44 Expected volatility 142.1 % 86.7 % Risk-free interest rate 0.7 % 2.3 % Expected holding period, in years 6.1 5.7 Dividend yield — % — %

Restructuring and Other Related

Restructuring and Other Related Charges	9 Months Ended
	Sep. 30, 2020
Restructuring And Related Activities [Abstract]
Restructuring and Other Related Charges	Note 16. Restructuring and Other Related Charges In January 2020, the Company entered into a separation agreement with a former officer. This agreement required an aggregate severance payment of $190,000 over a six-month period. Also, in January 2020, the Company entered into an agreement with a new employee that requires the unconditional payment of $175,000, in lieu of future severance. Payment is to be made in equal monthly installments over a fourteen-month period. Restructuring and other related charges for the three months ended September 30, 2019 of $ 804,643 Restructuring and other related charges for the nine months ended September 30, 2019 The following table provides a summary of the Company’s restructuring and other related charges for the three and nine months ended September 30, 2020 2019 Three months ended September 30, Nine months ended September 30, 2020 2019 2020 2019 Employee separation costs $ — $ 804,643 $ 271,164 $ 1,997,292 Payment in lieu of severance — — 175,000 — Other restructuring costs — — 18,442 — $ — $ 804,643 $ 464,606 $ 1,997,292 As of September 30, 2020 30, 2020

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2020
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 17. Commitments and Contingencies Stockholders Litigation On July 8, 2019 and August 1, 2019, purported stockholders of the Company served putative class action lawsuits in the Superior Court of New Jersey for Somerset County, captioned Paul Kuehl vs. electroCore, Inc., et al., Docket No. SOM-L 000876-19 and Shirley Stone vs. electroCore, Inc., et al., Docket No. SOM-L 001007-19, respectively. In addition to the Company, the defendants include present and past directors and officers, Evercore Group L.L.C., Cantor Fitzgerald & Co., JMP Securities LLC and BTIG, LLC, the underwriters for its IPO; and two of the Company’s stockholders. On August 15, 2019, the Superior Court entered an order consolidating the Kuehl and Stone actions, which are proceeding under Docket No. SOM-L 000876-19. Each plaintiff was appointed a co-lead plaintiff. The plaintiffs filed a consolidated amended complaint, which sought certification of a class of stockholders who purchased common stock in the IPO or whose purchases are traceable to that offering. The consolidated amended complaint alleged that the defendants violated Sections 11, 12(a)(2) and 15 of the Securities Act with respect to the registration statement and related prospectus for the IPO. The complaint sought unspecified compensatory damages, interest, costs and attorneys’ fees. On October 31, 2019, the Company and the other defendants filed a motion to dismiss the complaint or in the alternative to stay the action in favor of the pending federal action (discussed below). On February 21, 2020 the court granted the defendants’ motion to dismiss the consolidated amended complaint with prejudice. On March 2, 2020 the court entered an amended order dismissing the consolidated amended complaint with prejudice. On March 27, 2020, the plaintiffs filed a notice of appeal with the N.J. Superior Court-Appellate Division. The appeal was fully briefed as of July 17, 2020. The date for argument of the appeal has not yet been set. On September 26, 2019 and October 31, 2019, purported stockholders of the Company served putative class action lawsuits in the United States District Court for the District of New Jersey captioned Allyn Turnofsky vs. electroCore, Inc., et al., Case 3:19-cv-18400, and Priewe vs. electroCore, Inc., et al., Case 1:19-cv-19653, respectively. In addition to the Company, the defendants include present and past directors and officers, and Evercore Group L.L.C., Cantor Fitzgerald & Co., JMP Securities LLC and BTIG, LLC, the underwriters for the IPO. The plaintiffs each seek to represent a class of stockholders who (i) purchased the Company’s common stock in the IPO or whose purchases are traceable to the IPO, or (ii) who purchased common stock between the IPO and September 25, 2019. The complaints each alleged that the defendants violated Sections 11 and 15 of the Securities Act and Sections 10(b) and 20(a) of the Exchange Act, with respect to (i) the registration statement and related prospectus for the IPO, and (ii) certain post-IPO disclosures filed with the SEC. The complaints sought unspecified compensatory damages, interest, costs and attorneys’ fees. In the Turnofsky case, on November 25, 2019 several plaintiffs and their counsel moved to be selected as lead plaintiff and lead plaintiff’s counsel. On April 24, 2020, the Court granted the motion of Carole Tibbs and the firm Bragar, Eagel & Squire, P.C. On July 17, 2020 the plaintiffs filed an amended complaint in Turnofsky. In addition to the prior claims, the amended complaint adds an additional director defendant and two investors as defendants and adds a claim against the Company and the underwriters for violating Section 12(a)(2) of the Securities Act. On September 15, 2020, the Company and the other defendants filed a motion to dismiss the amended complaint for failure to state a claim. On November 6, 2020, The Priewe case was voluntarily dismissed on February 19, 2020. The Company intends to continue to vigorously defend itself in these matters. However, in light of, among other things, the preliminary stage of these litigation matters, the Company is unable to determine the reasonable probability of loss or a range of potential loss. Accordingly, the Company has not established an accrual for potential losses, if any, that could result from any unfavorable outcome, and there can be no assurance that these litigation matters will not result in substantial defense costs and/or judgements or settlements that could adversely affect the Company’s financial condition. The Company expenses legal fees associated with these stockholder litigations in the period in which they are incurred. Settlement Agreement In January 2019, the Company settled a dispute with one of its former advisors, Madison Global Partners ("Madison Global"), which had filed a complaint against the Company in the Supreme Court of the State of New York, County of New York (Index No. 652329/2018). As part of that settlement, the Company paid Madison Global $325,000 and issued to Madison Global and its representatives warrants to purchase in the aggregate 62,181 shares of its common stock at prices ranging from $5.68 per share to $12.60 per share. In January 2019, 5,192 ollowing table # Warrants Exercise Price Expiration Dates 8,576 $ 8.86 April 1, 2021 22,253 $ 5.68 March 30, 2022 17,066 $ 12.60 June 30, 2022 14,286 $ 12.60 August 31, 2022

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2020
Accounting Policies [Abstract]
Basis of Presentation	(a) Basis of Presentation The accompanying condensed consolidated financial statements were prepared in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”) and with instructions to Form 10-Q and Article 10 of Regulation S-X under the Securities Exchange Act of 1934, as amended. In the opinion of management, the Company has made all necessary adjustments, which include normal recurring adjustments necessary for a fair presentation of the Company’s condensed consolidated financial position and results of operations for the interim periods presented. Certain information and disclosures normally included in the annual consolidated financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. These interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and accompanying notes for the year ended included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 30 2020 are not necessarily indicative of the results to be expected for a full year, any other interim periods or any future year or period.
Principles of Consolidation	(b) Principles of Consolidation The accompanying condensed consolidated financial statements include the accounts of electroCore and its wholly owned subsidiaries. electroCore Australia, a VIE for which electroCore is the primary beneficiary, is also consolidated with the non-controlled equity presented as a non-controlling interest. All intercompany balances and transactions have been eliminated in consolidation.
Use of Estimates	(c) Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of these condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant items subject to such estimates and assumptions include allowances for doubtful accounts, trade credits, rebates, co-payment assistance and sales returns, valuation of inventory , stock compensation, and contingencies.
Credit Losses on Financial Instruments	(d) Credit Losses on Financial Instruments In June 2016, the Financial Accounting Standard Board ("FASB") issued guidance on the measurement of credit losses which requires measurement and recognition of expected credit losses for financial assets, including trade receivables held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. The method to determine a loss is different from the existing guidance, which requires a credit loss to be recognized when it is probable. The Company adopted this guidance and determined the impact was immaterial on the consolidated to the financial statements.
Fair Value Measurement	(e) Fair Value Measurement In August 2018, the FASB issued guidance which modified the disclosure requirements for fair value measurements. The guidance is effective for the year ended December 31, 2020. The Company adopted this guidance and it was properly reflected in the condensed consolidated financial statements. There were no material changes to the prior disclosure.
Recent Accounting Standards Not Yet Adopted	(f) Recent Accounting Standards Not Yet Adopted In December 2019, the FASB issued an update to simplify the accounting for income taxes and improve consistent application by clarifying or amending existing guidance. This guidance is effective for the year ended December 31, 2021. The Company does not expect this guidance to have a material impact on its consolidated financial statements upon adoption.

Revenue Recognition (Tables)

Revenue Recognition (Tables)	9 Months Ended
	Sep. 30, 2020
Revenue From Contract With Customer [Abstract]
Schedule of net sales disaggregated by geographic area	For the three months ended September 30, For 2020 2019 2020 2019 Geographic Market United States $ 800,767 $ 491,722 $ 1,759,477 $ 1,211,318 Europe 278,340 187,639 801,055 494,765 Other 1,734 3,632 7,035 9,254 Total Net Sales $ 1,080,841 $ 682,993 $ 2,567,567 $ 1,715,337

Cash, Cash Equivalents and Ma_2

Cash, Cash Equivalents and Marketable Securities (Tables)	9 Months Ended
	Sep. 30, 2020
Investments Debt And Equity Securities [Abstract]
Schedule of cash, cash equivalents and marketable securities	As of Amortized Cost Unrealized Gain Unrealized (Loss) Fair Value Cash and cash equivalents $ 3,832,454 $ — $ — $ 3,832,454 U.S. Treasury Bonds $ 22,138,304 $ — $ (3,093 ) $ 22,135,211 Total marketable securities $ 22,138,304 $ — $ (3,093 ) $ 22,135,211 Total cash, cash equivalents, and marketable securities $ 25,970,758 $ — $ (3,093 ) $ 25,967,665 A s of December 31, 2019 Amortized Cost Unrealized Gain Unrealized (Loss) Fair Value Cash and cash equivalents $ 13,564,252 $ — $ (461 ) $ 13,563,791 U.S. Treasury Bonds $ 10,494,539 $ 811 $ — $ 10,495,350 Total marketable securities $ 10,494,539 $ 811 $ — $ 10,495,350 Total cash, cash equivalents, and marketable securities $ 24,058,791 $ 811 $ (461 ) $ 24,059,141

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2020
Fair Value Disclosures [Abstract]
Schedule of assets and liabilities carried at fair value	Fair Value Hierarchy September 30, 2020 Total Level 1 Level 2 Level 3 Assets Cash and cash equivalents $ 3,832,454 $ 3,832,454 $ — $ — Marketable Securities: U.S. treasury bonds 22,135,211 22,135,211 — — Total $ 25,967,665 $ 25,967,665 $ — $ — Fair Value Hierarchy December 31, 2019 Total Level 1 Level 2 Level 3 Assets Cash and cash equivalents $ 13,563,791 $ 13,563,791 $ — $ — Marketable Securities: U.S. treasury bonds 10,495,350 10,495,350 — — Total $ 24,059,141 $ 24,059,141 $ — $ —

Inventories (Tables)

Inventories (Tables)	9 Months Ended
	Sep. 30, 2020
Inventory Disclosure [Abstract]
Schedule of inventories stated at lower of cost or market	September 30, December 31, 2020 2019 Raw materials $ 1,503,808 $ 1,065,345 Work in process 4,656,723 5,314,763 Finished goods 766,563 531,064 Total inventory 6,927,094 6,911,172 Less: noncurrent (6,133,878 ) (6,020,180 ) Total - current $ 793,216 $ 890,992

Leases (Tables)

Leases (Tables)	9 Months Ended
	Sep. 30, 2020
Leases [Abstract]
Schedule of supplemental balance sheet information for operating leases	September 30, 2020 December 31, 2019 Operating leases: Operating lease right of use assets $ 1,153,939 $ 1,430,641 Operating lease liabilities: Current portion of operating lease liabilities 514,934 486,445 Noncurrent operating lease liabilities 1,036,117 1,419,880 Total operating lease liabilities $ 1,551,051 $ 1,906,325 Weighted average remaining lease term (in years) 5.7 5.9 Weighted average discount rate 13.75 % 13.75 %
Schedule of supplemental statement of cash flows information for operating leases	Nine months ended September 30, 2020 2019 Noncash lease expense $ 273,070 $ 232,270 Change in operating lease liabilities $ (355,274 ) $ 178,872
Schedule of future minimum lease payments under non-cancellable operating leases	Remainder of 2020 $ 127,959 2021 743,818 2022 337,254 2023 142,892 2024 146,044 2025 and thereafter 676,260 Total future minimum lease payments 2,174,227 Less: Amounts representing interest (623,176 ) Total $ 1,551,051

Accrued Expenses and Other Cu_2

Accrued Expenses and Other Current Liabilities (Tables)	9 Months Ended
	Sep. 30, 2020
Payables and Accruals [Abstract]
Schedule of accrued expenses	September 30, December 31, 2020 2019 Accrued professional fees $ 411,880 $ 1,255,494 Accrued bonuses 1,105,166 804,082 Other employee related expenses 415,441 836,754 Other 603,454 441,049 $ 2,535,941 $ 3,337,379

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	9 Months Ended
	Sep. 30, 2020
Earnings Per Share [Abstract]
Schedule of common stock equivalents excluded from computation of diluted loss per share	Nine months ended September 30, 2020 2019 Outstanding stock options 3,693,943 2,355,366 Nonvested restricted stock and unit awards 1,230,651 2,387,106 Stock purchase warrants 715,199 715,199 5,639,793 5,457,671

Stock Based Compensation (Table

Stock Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2020
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Schedule of activity related to stock options	Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Outstanding, January 1, 2020 3,131,266 $ 8.53 8.9 * Granted 1,844,298 1.28 * Exercised — — Cancelled (1,281,621 ) 11.79 * Outstanding, September 30, 2020 3,693,943 $ 5.86 8.7 $ 553,826 Exercisable, September 30, 2020 1,076,615 $ 10.97 7.7 $ 34,347 * de minimis
Schedule of activity related to restricted stock awards granted	Number of Shares Weighted Average Grant Date Fair Value Nonvested January 1, 2020 127,505 $ 8.09 Granted — — Vested (53,662 ) 9.55 Cancelled (19,946 ) 9.52 Nonvested, September 30, 2020 53,897 $ 6.10
Schedule of activity related to restricted stock and deferred stock units granted	Number of Shares Weighted Average Grant Date Fair Value Nonvested, January 1, 2020 1,241,493 $ 2.86 Granted 732,140 0.91 Vested (528,238 ) 2.46 Cancelled (268,641 ) 4.08 Nonvested, September 30, 2020 1,176,754 $ 1.55
Schedule of recognized stock compensation for equity awards	Three months ended September 30, Nine months ended September 30, 2020 2019 2020 2019 Selling, general and administrative $ 541,757 $ 904,115 $ 1,789,122 $ 2,030,465 Research and development 179,664 313,533 649,485 658,014 Cost of goods sold 21,507 1,927 51,944 1,927 Total expense $ 742,928 $ 1,219,575 $ 2,490,551 $ 2,690,406
Schedule of weighted average assumptions used in valuing plans	Nine months ended September 30, 2020 Nine months ended September 30, 2019 Fair value at grant date $ 0.98 $ 4.44 Expected volatility 142.1 % 86.7 % Risk-free interest rate 0.7 % 2.3 % Expected holding period, in years 6.1 5.7 Dividend yield — % — %

Restructuring and Other Relat_2

Restructuring and Other Related Charges (Tables)	9 Months Ended
	Sep. 30, 2020
Restructuring And Related Activities [Abstract]
Schedule of restructuring and other related charges	Three months ended September 30, Nine months ended September 30, 2020 2019 2020 2019 Employee separation costs $ — $ 804,643 $ 271,164 $ 1,997,292 Payment in lieu of severance — — 175,000 — Other restructuring costs — — 18,442 — $ — $ 804,643 $ 464,606 $ 1,997,292

Commitments and Contingencies (

Commitments and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2020
Commitments And Contingencies Disclosure [Abstract]
Schedule of warrants issued	# Warrants Exercise Price Expiration Dates 8,576 $ 8.86 April 1, 2021 22,253 $ 5.68 March 30, 2022 17,066 $ 12.60 June 30, 2022 14,286 $ 12.60 August 31, 2022

Risks and Uncertainties - Addit

Risks and Uncertainties - Additional Information (Details) - USD ($)	May 14, 2020	May 06, 2020	May 04, 2020	Jul. 30, 2020	May 31, 2020	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Mar. 27, 2020	Dec. 31, 2019
Risks And Uncertainties [Line Items]
Value of shares issued						$ 45,199		$ 45,199			$ 29,835
Proceeds from notes issued				$ 1,200,000				2,558,360	$ 807,347
Sale of net operating losses		$ 1,200,000
Incurred loss						$ 4,500,000		$ 17,200,000
Net Sales
Risks And Uncertainties [Line Items]
Percentage of net sales						84.00%	63.40%	87.20%	47.50%
Promissory Note | Citibank, N.A. | Paycheck Protection Program
Risks And Uncertainties [Line Items]
Proceeds from notes issued			$ 1,400,000		$ 1,400,000
Lincoln Park
Risks And Uncertainties [Line Items]
Aggregate proceeds from sale of common stock								$ 17,100,000
Stock Purchase Agreement | Lincoln Park
Risks And Uncertainties [Line Items]
Value of shares issued										$ 5,000,000
Aggregate proceeds from sale of common stock								$ 9,900,000
Additional shares of common stock								9,900,000
Stock Purchase Agreement | Lincoln Park | Maximum
Risks And Uncertainties [Line Items]
Value of shares issued										$ 25,000,000
Securities Purchase Agreement
Risks And Uncertainties [Line Items]
Issuance of stock, shares	1,564,345
Shares issued price per share	$ 0.99
New Jersey Technology Business Tax Certificate Transfer (NOL) Program
Risks And Uncertainties [Line Items]
Sale of net operating losses		$ 1,200,000

Revenue Recognition - Summary o

Revenue Recognition - Summary of Net Sales Disaggregated by Geographic Area (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Disaggregation Of Revenue [Line Items]
Total Net Sales	$ 1,080,841	$ 682,993	$ 2,567,567	$ 1,715,337
United States
Disaggregation Of Revenue [Line Items]
Total Net Sales	800,767	491,722	1,759,477	1,211,318
Europe
Disaggregation Of Revenue [Line Items]
Total Net Sales	278,340	187,639	801,055	494,765
Other
Disaggregation Of Revenue [Line Items]
Total Net Sales	$ 1,734	$ 3,632	$ 7,035	$ 9,254

Revenue Recognition - Additiona

Revenue Recognition - Additional Information (Details)	9 Months Ended
	Sep. 30, 2020
Revenue From Contract With Customer [Abstract]
Payment term for customers	30 days

Cash, Cash Equivalents and Ma_3

Cash, Cash Equivalents and Marketable Securities - Summary of Cash, Cash Equivalents, and Marketable Securities (Details) - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Schedule Of Available For Sale Securities [Line Items]
Cash and Cash Equivalents, Amortized Cost	$ 3,832,454	$ 13,564,252
Cash and Cash Equivalents, Unrealized Gain
Cash and Cash Equivalents, Unrealized (Loss)		(461)
Cash and cash equivalents	3,832,454	13,563,791
Marketable securities, Amortized Cost	22,138,304	10,494,539
Marketable securities, Unrealised Gain		811
Marketable securities, Unrealized (Loss)	(3,093)
Marketable securities, Fair Value	22,135,211	10,495,350
Cash, cash equivalents, and marketable securities, Amortized Cost	25,970,758	24,058,791
Cash, cash equivalents, and marketable securities, Unrealized Gain		811
Cash, cash equivalents, and marketable securities, Unrealized (Loss)	(3,093)	(461)
Cash, cash equivalents, and marketable securities, Fair Value	25,967,665	24,059,141
U.S. Treasury Bonds
Schedule Of Available For Sale Securities [Line Items]
Marketable securities, Amortized Cost	22,138,304	10,494,539
Marketable securities, Unrealised Gain		811
Marketable securities, Unrealized (Loss)	(3,093)
Marketable securities, Fair Value	22,135,211	10,495,350
Cash, cash equivalents, and marketable securities, Fair Value	$ 22,135,211	$ 10,495,350

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Assets and Liabilities Carried at Fair Value (Details) - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Cash and cash equivalents	$ 3,832,454	$ 13,563,791
Marketable Securities	25,967,665	24,059,141
U.S. Treasury Bonds
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Marketable Securities	22,135,211	10,495,350
Level 1
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Cash and cash equivalents	3,832,454	13,563,791
Marketable Securities	25,967,665	24,059,141
Level 1 | U.S. Treasury Bonds
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Marketable Securities	22,135,211	10,495,350
Level 2
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Cash and cash equivalents
Marketable Securities
Level 2 | U.S. Treasury Bonds
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Marketable Securities
Level 3
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Cash and cash equivalents
Marketable Securities
Level 3 | U.S. Treasury Bonds
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Marketable Securities

Inventories - Inventories (Deta

Inventories - Inventories (Details) - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Inventory Disclosure [Abstract]
Raw materials	$ 1,503,808	$ 1,065,345
Work in process	4,656,723	5,314,763
Finished goods	766,563	531,064
Total inventory	6,927,094	6,911,172
Less: noncurrent	(6,133,878)	(6,020,180)
Total - current	$ 793,216	$ 890,992

Inventories - Additional Inform

Inventories - Additional Information (Details) - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Inventory [Line Items]
Noncurrent inventory raw materials	$ 1,800,000	$ 1,000,000
Noncurrent inventory work in process	4,300,000	5,000,000
Inventory Valuation and Obsolescence [Member]
Inventory [Line Items]
Reserves for obsolete inventory	$ 287,544	$ 287,544

Leases - Supplemental Balance S

Leases - Supplemental Balance Sheet Information for Operating Leases (Details) - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Operating leases:
Operating lease right of use assets	$ 1,153,939	$ 1,430,641
Operating Lease, Liability [Abstract]
Current portion of operating lease liabilities	514,934	486,445
Noncurrent operating lease liabilities	1,036,117	1,419,880
Total operating lease liabilities	$ 1,551,051	$ 1,906,325
Weighted average remaining lease term (in years)	5 years 8 months 12 days	5 years 10 months 24 days
Weighted average discount rate	13.75%	13.75%

Leases - Supplemental Statement

Leases - Supplemental Statement of Cash Flows Information for Operating Leases (Details) - USD ($)	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Leases [Abstract]
Noncash lease expense	$ 273,070	$ 232,270
Change in operating lease liabilities	$ (355,274)	$ 178,872

Leases - Future Minimum Lease P

Leases - Future Minimum Lease Payments under Non-Cancellable Operating Leases (Details) - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Leases [Abstract]
Remainder of 2020	$ 127,959
2021	743,818
2022	337,254
2023	142,892
2024	146,044
2025 and thereafter	676,260
Total future minimum lease payments	2,174,227
Less: Amounts representing interest	(623,176)
Total	$ 1,551,051	$ 1,906,325

Leases - Additional Information

Leases - Additional Information (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Leases [Abstract]
Recognized lease expenses	$ 149,731	$ 186,037	$ 422,765	$ 599,322

Cloud Computing Arrangement - A

Cloud Computing Arrangement - Additional Information (Details) - USD ($)	3 Months Ended	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2020	Dec. 31, 2019
Cloud Computing Arrangement [Line Items]
Amortization of cloud computing arrangement	$ 70,519	$ 211,556
Remaining lease term	3 years	3 years
Other Assets [Member]
Cloud Computing Arrangement [Line Items]
Net book value of cloud computing arrangement	$ 869,729	$ 869,729	$ 1,081,284

Accrued Expenses and Other Cu_3

Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses (Details) - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Accrued Liabilities Current [Abstract]
Accrued professional fees	$ 411,880	$ 1,255,494
Accrued bonuses	1,105,166	804,082
Other employee related expenses	415,441	836,754
Other	603,454	441,049
Accrued expenses	$ 2,535,941	$ 3,337,379

Notes Payable - Additional Info

Notes Payable - Additional Information (Details) - USD ($)	May 04, 2020	Jul. 30, 2020	May 31, 2020	Sep. 30, 2020	Sep. 30, 2020	Sep. 30, 2019
Notes Payable [Line Items]
Proceeds from borrowings		$ 1,200,000			$ 2,558,360	$ 807,347
Interest rate on the Loan		2.18%
Interest expense				$ 3,574	3,574
Note, maturity date	Feb. 2, 2023
Monthly installments payable		$ 164,800
Remaining balance of notes payable				$ 654,563	$ 654,563
Promissory Note | Citibank, N.A. | Paycheck Protection Program
Notes Payable [Line Items]
Proceeds from borrowings	$ 1,400,000		$ 1,400,000
Interest rate on the Loan	1.00%

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Details) - USD ($)	May 14, 2020	Apr. 14, 2020	May 18, 2020	Sep. 30, 2020	Mar. 27, 2020	Dec. 31, 2019
Stock Purchase Agreement [Line Items]
Value of shares issued				$ 45,199		$ 29,835
Common stock, shares issued				45,199,088		29,835,183
Lincoln Park
Stock Purchase Agreement [Line Items]
Aggregate proceeds from sale of common stock				$ 17,100,000
Stock Purchase Agreement | Lincoln Park
Stock Purchase Agreement [Line Items]
Value of shares issued					$ 5,000,000
Common stock, shares issued				9,979,676	461,676
Fair value of common stock shares issued					$ 186,300
Additional commitment shares issued				692,514	230,838
Aggregate proceeds from sale of common stock				$ 9,900,000
Aggregate proceeds				15,100,000
Stock Purchase Agreement | Lincoln Park | Maximum
Stock Purchase Agreement [Line Items]
Value of shares issued					$ 25,000,000
First SPA
Stock Purchase Agreement [Line Items]
Aggregate proceeds from sale of common stock		$ 1,750,000
Aggregate number of shares issued		2,058,822
Shares issued. price per share		$ 0.85
Second SPA
Stock Purchase Agreement [Line Items]
Shares issued. price per share	$ 0.99
Issuance of stock, shares	1,564,345
Non-cash charge				$ 156,434
Third SPA
Stock Purchase Agreement [Line Items]
Aggregate proceeds from sale of common stock			$ 450,000
Aggregate number of shares issued			505,205
Shares issued. price per share			$ 0.9178

Net Loss Per Share - Schedule o

Net Loss Per Share - Schedule of Common Stock Equivalents Excluded from Computation of Diluted Loss per Share (Details) - shares	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	5,639,793	5,457,671
Outstanding stock options
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	3,693,943	2,355,366
Nonvested restricted stock and unit awards
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	1,230,651	2,387,106
Stock purchase warrants
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	715,199	715,199

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - USD ($)	May 06, 2020	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Operating Loss Carryforwards [Line Items]
Sale of net operating losses	$ 1,200,000
Provision for income taxes				$ (1,170,890)
New Jersey Technology Business Tax Certificate Transfer (NOL) Program
Operating Loss Carryforwards [Line Items]
Sale of net operating losses	$ 1,200,000

Stock Based Compensation - Summ

Stock Based Compensation - Summary of Activity Related to Stock Options (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2020	Dec. 31, 2019
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Number of Options, Outstanding, January 1, 2020	3,131,266
Number of Options, Granted	1,844,298
Number of Options, Exercised
Number of Options, Cancelled	(1,281,621)
Number of Options, Outstanding, September 30, 2020	3,693,943	3,131,266
Number of Options, Exercisable, September 30, 2020	1,076,615
Weighted Average Exercise Price, Outstanding, January 1, 2020	$ 8.53
Weighted Average Exercise Price, Granted	1.28
Weighted Average Exercise Price, Exercised
Weighted Average Exercise Price, Cancelled	11.79
Weighted Average Exercise Price, Outstanding, September 30, 2020	5.86	$ 8.53
Weighted Average Exercise Price, Exercisable, September 30, 2020	$ 10.97
Weighted Average Remaining Contractual Term (Years), Outstanding, January 1, 2020	8 years 8 months 12 days	8 years 10 months 24 days
Weighted Average Remaining Contractual Term (Years), Exercisable, September 30, 2020	7 years 8 months 12 days
Aggregate Intrinsic Value, Outstanding, September 30, 2020	$ 553,826
Aggregate Intrinsic Value, Exercisable, September 30, 2020	$ 34,347

Stock Based Compensation - Addi

Stock Based Compensation - Additional Information (Details)	9 Months Ended
	Sep. 30, 2020USD ($)
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period	4 years
Unrecognized compensation cost related to unvested awards	$ 5.7
Unrecognized compensation expected to be recognized	2 years 4 months 24 days
RSAs [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period	4 years
RSAs [Member] | Non-Executive Director
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period	1 year
Stock Units
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period	3 years
Stock Units | Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period	2 years
Stock Units | Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period	4 years

Stock Based Compensation - Su_2

Stock Based Compensation - Summary of Activity Related to Restricted Stock Awards Granted (Details) - RSAs [Member]	9 Months Ended
	Sep. 30, 2020$ / sharesshares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Shares, Nonvested, January 1,2020 | shares	127,505
Number of Shares, Granted | shares
Number of Shares, Vested | shares	(53,662)
Number of Shares, Cancelled | shares	(19,946)
Number of Shares, Nonvested, September 30, 2020 | shares	53,897
Weighted Average Grand Date Fair Value, Nonvested, January 1, 2020 | $ / shares	$ 8.09
Weighted Average Grand Date Fair Value, Granted | $ / shares
Weighted Average Grand Date Fair Value, Vested | $ / shares	9.55
Weighted Average Grand Date Fair Value, Cancelled | $ / shares	9.52
Weighted Average Grand Date Fair Value, Nonvested, September 30, 2020 | $ / shares	$ 6.10

Stock Based Compensation - Su_3

Stock Based Compensation - Summary of Activity Related to Restricted Stock and Deferred Stock Units Granted (Details) - Stock Units	9 Months Ended
	Sep. 30, 2020$ / sharesshares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Shares, Nonvested, January 1,2020 | shares	1,241,493
Number of Shares, Granted | shares	732,140
Number of Shares, Vested | shares	(528,238)
Number of Shares, Cancelled | shares	(268,641)
Number of Shares, Nonvested, September 30, 2020 | shares	1,176,754
Weighted Average Grand Date Fair Value, Nonvested, January 1, 2020 | $ / shares	$ 2.86
Weighted Average Grand Date Fair Value, Granted | $ / shares	0.91
Weighted Average Grand Date Fair Value, Vested | $ / shares	2.46
Weighted Average Grand Date Fair Value, Cancelled | $ / shares	4.08
Weighted Average Grand Date Fair Value, Nonvested, September 30, 2020 | $ / shares	$ 1.55

Stock Based Compensation - Sche

Stock Based Compensation - Schedule of Recognized Stock Compensation for Equity Awards (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock based compensation	$ 742,928	$ 1,219,575	$ 2,490,551	$ 2,690,406
Selling, General and Administrative
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock based compensation	541,757	904,115	1,789,122	2,030,465
Research and Development
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock based compensation	179,664	313,533	649,485	658,014
Cost of Goods Sold
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock based compensation	$ 21,507	$ 1,927	$ 51,944	$ 1,927

Stock Based Compensation - Su_4

Stock Based Compensation - Summary of Weighted Average Assumptions Used in Valuing Plans (Details) - $ / shares	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Fair value at grant date	$ 0.98	$ 4.44
Expected volatility	142.10%	86.70%
Risk-free interest rate	0.70%	2.30%
Expected holding period, in years	6 years 1 month 6 days	5 years 8 months 12 days
Dividend yield

Restructuring and Other Relat_3

Restructuring and Other Related Charges - Additional Information (Details) - USD ($)	Jan. 31, 2020	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Restructuring Cost And Reserve [Line Items]
Aggregate severance payment			$ 804,643	$ 271,164	$ 1,997,292
Restructuring and other related expense			$ 804,643	464,606	$ 1,997,292
Amount payable in connection with restructuring charges		$ 62,500		$ 62,500
Employee Severance | Former Officer
Restructuring Cost And Reserve [Line Items]
Aggregate severance payment	$ 190,000
Employee Severance | New Employee
Restructuring Cost And Reserve [Line Items]
Aggregate severance payment	$ 175,000

Restructuring and Other Relat_4

Restructuring and Other Related Charges - Summary of Restructuring and Other Related Charges (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Restructuring Cost And Reserve [Line Items]
Employee separation costs		$ 804,643	$ 271,164	$ 1,997,292
Payment in lieu of severance			175,000
Other restructuring costs			18,442
Restructuring and other related charges		$ 804,643	$ 464,606	$ 1,997,292

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Details)	Jul. 17, 2020InvestorsAsDefendents	Jan. 31, 2019USD ($)Dispute$ / sharesshares
Class Of Warrant Or Right [Line Items]
Number of investors as defendants | InvestorsAsDefendents	2
Number of Warrants | shares		5,192
Exercise price of warrants		$ 5.68
Former Financial Advisor
Class Of Warrant Or Right [Line Items]
Number of dispute settled | Dispute		1
Cash paid in settlement agreement | $		$ 325,000
Former Financial Advisor | Common Stock
Class Of Warrant Or Right [Line Items]
Warrants to purchase common stock | shares		62,181
Former Financial Advisor | Common Stock | Minimum
Class Of Warrant Or Right [Line Items]
Exercise price of warrants		$ 5.68
Former Financial Advisor | Common Stock | Maximum
Class Of Warrant Or Right [Line Items]
Exercise price of warrants		$ 12.60

Commitments and Contingencies_2

Commitments and Contingencies - Schedule of Warrants Issued (Details)	Jan. 31, 2019$ / sharesshares
Class Of Warrant Or Right [Line Items]
Number of Warrants | shares	5,192
Exercise Price | $ / shares	$ 5.68
Warrant One
Class Of Warrant Or Right [Line Items]
Number of Warrants | shares	8,576
Exercise Price | $ / shares	$ 8.86
Expiration Dates	Apr. 1, 2021
Warrant Two
Class Of Warrant Or Right [Line Items]
Number of Warrants | shares	22,253
Exercise Price | $ / shares	$ 5.68
Expiration Dates	Mar. 30, 2022
Warrant Three
Class Of Warrant Or Right [Line Items]
Number of Warrants | shares	17,066
Exercise Price | $ / shares	$ 12.60
Expiration Dates	Jun. 30, 2022
Warrant Four
Class Of Warrant Or Right [Line Items]
Number of Warrants | shares	14,286
Exercise Price | $ / shares	$ 12.60
Expiration Dates	Aug. 31, 2022